Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Nathalie Goemans, Eugenio Mercuri, Е. Д. Белоусова, et al.
Neuromuscular Disorders (2017) Vol. 28, Iss. 1, pp. 4-15
Open Access | Times Cited: 115

Showing 26-50 of 115 citing articles:

Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Derek Hong, Lilia M. Iakoucheva
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 16
A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies
Ahlke Heydemann, Maria Siemionow
Biomedicines (2023) Vol. 11, Iss. 3, pp. 830-830
Open Access | Times Cited: 14
Non-viral delivery of nucleic acid for treatment of rare diseases of the muscle
Divya Rao, Munia Ganguli
Journal of Biosciences (2024) Vol. 49, Iss. 1
Closed Access | Times Cited: 6
Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304984-e0304984
Open Access | Times Cited: 5
Personalized gene and cell therapy for Duchenne Muscular Dystrophy
Florian Barthélémy, Nicolas Wein
Neuromuscular Disorders (2018) Vol. 28, Iss. 10, pp. 803-824
Open Access | Times Cited: 46
More than a messenger: Alternative splicing as a therapeutic target
Adam J. Black, Jennifer R. Gamarra, Jimena Giudice
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2019) Vol. 1862, Iss. 11-12, pp. 194395-194395
Open Access | Times Cited: 36
Duchenne muscular dystrophy: an historical treatment review
Lineu César Werneck, Paulo José Lorenzoni, Renata Dal‐Prá Ducci, et al.
Arquivos de Neuro-Psiquiatria (2019) Vol. 77, Iss. 8, pp. 579-589
Open Access | Times Cited: 36
Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers
Neil Datta, Partha S. Ghosh
Current Neurology and Neuroscience Reports (2020) Vol. 20, Iss. 6
Closed Access | Times Cited: 36
Exon-Skipping in Duchenne Muscular Dystrophy
Shin’ichi Takeda, Paula R. Clemens, Eric P. Hoffman
Journal of Neuromuscular Diseases (2021) Vol. 8, Iss. s2, pp. S343-S358
Open Access | Times Cited: 32
RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays
Zhichao Tang, Junxing Zhao, Zachary Pearson, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2263-2263
Open Access | Times Cited: 29
Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy
Giulia Ricci, Luca Bello, Francesca Torri, et al.
Neurological Sciences (2022) Vol. 43, Iss. S2, pp. 625-633
Open Access | Times Cited: 20
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
J. van Deutekom, Chantal Beekman, Suzanne Bijl, et al.
Nucleic Acid Therapeutics (2023) Vol. 33, Iss. 3, pp. 193-208
Open Access | Times Cited: 13
Nucleic acid therapeutics as differentiation agents for myeloid leukemias
Olivia Kovecses, François Mercier, Maureen McKeague
Leukemia (2024) Vol. 38, Iss. 7, pp. 1441-1454
Open Access | Times Cited: 4
Antisense oligonucleotides and their applications in rare neurological diseases
Simon McDowall, May T. Aung-Htut, Steve D. Wilton, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 4
Current and Emerging Therapies for Duchenne Muscular Dystrophy
Megan Crone, Jean K. Mah
Current Treatment Options in Neurology (2018) Vol. 20, Iss. 8
Closed Access | Times Cited: 36
Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
Mirko Signorelli, Burcu Ayoglu, Camilla Johansson, et al.
Journal of Cachexia Sarcopenia and Muscle (2019) Vol. 11, Iss. 2, pp. 505-517
Open Access | Times Cited: 35
Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy
Craig M. McDonald, Brenda Wong, Kevin M. Flanigan, et al.
Annals of Clinical and Translational Neurology (2018) Vol. 5, Iss. 8, pp. 913-926
Open Access | Times Cited: 33
A new era in the management of Duchenne muscular dystrophy
Rudolf Korinthenberg
Developmental Medicine & Child Neurology (2018) Vol. 61, Iss. 3, pp. 292-297
Open Access | Times Cited: 33
Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy
Hirofumi Komaki, Yoshihiro Maegaki, Tsuyoshi Matsumura, et al.
Annals of Clinical and Translational Neurology (2020) Vol. 7, Iss. 2, pp. 181-190
Open Access | Times Cited: 31
Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review
Carlos Pascual‐Morena, Iván Cavero‐Redondo, Celia Álvarez‐Bueno, et al.
Annals of Clinical and Translational Neurology (2020) Vol. 7, Iss. 9, pp. 1738-1752
Open Access | Times Cited: 31
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration
Nathalie Goemans, Brenda Wong, M. van den Hauwe, et al.
PLoS ONE (2020) Vol. 15, Iss. 6, pp. e0232870-e0232870
Open Access | Times Cited: 30
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Maria Siemionow, Paulina Langa, Sonia Brodowska, et al.
Stem Cell Reviews and Reports (2022) Vol. 18, Iss. 8, pp. 2872-2892
Open Access | Times Cited: 17
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy
Katarzyna Chwalenia, Matthew J. A. Wood, Thomas C. Roberts
Journal of Muscle Research and Cell Motility (2025)
Open Access
Antisense RNA therapies for muscular dystrophies
Virginia Arechavala‐Gomeza, Andrea López‐Martínez, Annemieke Aartsma‐Rus
Journal of Neuromuscular Diseases (2025)
Closed Access
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies
Jaeho Hwang, Toshifumi Yokota
Expert Reviews in Molecular Medicine (2019) Vol. 21
Closed Access | Times Cited: 29

Scroll to top